MA56021A - Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 - Google Patents

Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Info

Publication number
MA56021A
MA56021A MA056021A MA56021A MA56021A MA 56021 A MA56021 A MA 56021A MA 056021 A MA056021 A MA 056021A MA 56021 A MA56021 A MA 56021A MA 56021 A MA56021 A MA 56021A
Authority
MA
Morocco
Prior art keywords
inhibitors
quinazoline derivatives
amino quinazoline
amino
derivatives
Prior art date
Application number
MA056021A
Other languages
English (en)
French (fr)
Inventor
Charles Baker-Glenn
Matteo Biagetti
Paolo Bruno
Claudio Fiorelli
Kim Louise Hirst
Daniele Pala
Daniela Pizzirani
Paolo Ronchi
De Poël Hervè Van
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA56021A publication Critical patent/MA56021A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
MA056021A 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 MA56021A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19177604 2019-05-31
EP19201168 2019-10-02

Publications (1)

Publication Number Publication Date
MA56021A true MA56021A (fr) 2022-04-06

Family

ID=70861506

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056021A MA56021A (fr) 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3
MA056022A MA56022A (fr) 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA056022A MA56022A (fr) 2019-05-31 2020-05-28 Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3

Country Status (20)

Country Link
US (2) US12466820B2 (https=)
EP (2) EP3976180A1 (https=)
JP (3) JP7644029B2 (https=)
KR (2) KR102921974B1 (https=)
CN (3) CN114269432B (https=)
AU (2) AU2020281923B2 (https=)
BR (2) BR112021022099A2 (https=)
CA (2) CA3139018A1 (https=)
CL (1) CL2021003165A1 (https=)
CO (1) CO2021017031A2 (https=)
GE (2) GEAP202515818A (https=)
IL (1) IL288405A (https=)
MA (2) MA56021A (https=)
MX (2) MX2021014115A (https=)
PE (1) PE20220934A1 (https=)
PH (1) PH12021552881A1 (https=)
SA (1) SA521430920B1 (https=)
SG (1) SG11202112187YA (https=)
WO (2) WO2020239951A1 (https=)
ZA (1) ZA202108273B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
CN114222741B (zh) * 2019-05-31 2025-12-30 奇斯药制品公司 作为p2x3抑制剂的吡啶并嘧啶类衍生物
CN114222737B (zh) 2019-05-31 2024-07-26 詹森药业有限公司 NF-κB诱导激酶的小分子抑制剂
WO2020243423A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
EP4234548A4 (en) * 2020-10-20 2024-10-23 Suzhou Zelgen Biopharmaceutical Co., Ltd. SUBSTITUTED BENZO OR PYRIDOPYRIMIDINE AMINE INHIBITOR, ITS PREPARATION METHOD AND ITS APPLICATION
AU2021388923A1 (en) * 2020-11-27 2023-05-25 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
JP2023550830A (ja) * 2020-11-27 2023-12-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体
CN112661803A (zh) * 2020-12-17 2021-04-16 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA 4-胺基喹唑啉化合物的合成方法
WO2022140456A1 (en) * 2020-12-22 2022-06-30 Mekanistic Therapeutics Llc Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
CN114907284B (zh) * 2021-02-10 2023-11-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN115677601B (zh) * 2021-07-29 2025-06-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2024235225A1 (zh) * 2023-05-15 2024-11-21 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
EP4716684A1 (en) 2023-05-22 2026-04-01 Chiesi Farmaceutici S.p.A. Salts of amino quinazoline derivatives
CN121368584A (zh) 2023-05-22 2026-01-20 奇斯药制品公司 用于制备p2x3抑制剂的方法及中间体
WO2025101598A1 (en) * 2023-11-07 2025-05-15 Zeno Management, Inc. Bi-cyclic pyrimidine compounds, methods and uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0710843A (ja) * 1993-03-31 1995-01-13 Eisai Co Ltd 含窒素縮合複素環化合物
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CN1930135B (zh) * 2004-03-05 2011-12-28 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3拮抗剂的二氨基嘧啶
CN102659774A (zh) * 2005-08-15 2012-09-12 弗·哈夫曼-拉罗切有限公司 作为p2x3拮抗剂的哌啶和哌嗪衍生物
JP4850914B2 (ja) 2005-09-01 2012-01-11 エフ．ホフマン−ラ ロシュ アーゲー Ｐ２ｘ３およびｐ２ｘ２／３モジュレーターとしてのジアミノピリミジン
EP2592070B1 (en) 2006-06-29 2016-08-31 F. Hoffmann-La Roche AG Tetrazole-substituted arylamides
CA2682162C (en) 2007-04-02 2016-05-10 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
JP5498374B2 (ja) 2007-04-17 2014-05-21 エボテック・アーゲー ２−シアノフェニル縮合複素環式化合物および組成物、ならびにその使用
MX2010009561A (es) 2008-02-29 2010-09-24 Renovis Inc Compuestos amida, composiciones y usos de los mismos.
CA2737038A1 (en) 2008-09-18 2010-03-25 Evotec Ag Amide compounds, compositions and uses thereof
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
CA2886139A1 (en) * 2012-12-27 2014-07-03 F. Hoffmann-La Roche Ag Comt inhibitors
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2016053794A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
WO2016084922A1 (ja) 2014-11-28 2016-06-02 塩野義製薬株式会社 １，２，４－トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
HUE058009T2 (hu) 2014-12-09 2022-06-28 Bayer Ag 1,3-Tiazol-2-il szubsztituált benzamid-származékok
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
KR20180054843A (ko) 2015-09-29 2018-05-24 애퍼런트 파마슈티컬스 인크. 기침 치료에 사용하기 위한 디아미노피리미딘 p2x3 및 p2x2/3 수용체 조정제
CA3006300C (en) * 2015-11-25 2024-02-27 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof
EP3478674B1 (en) * 2016-06-30 2020-05-13 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN109843858B (zh) * 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
JP7219218B2 (ja) 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
CA3056970A1 (en) * 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
TWI762634B (zh) 2017-05-05 2022-05-01 大陸商上海赫普化醫藥技術有限公司 胺基-芳基-苯甲醯胺化合物及其使用方法
CN114222741B (zh) 2019-05-31 2025-12-30 奇斯药制品公司 作为p2x3抑制剂的吡啶并嘧啶类衍生物
BR112021022099A2 (pt) 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3

Also Published As

Publication number Publication date
CL2021003165A1 (es) 2022-09-23
AU2020281923B2 (en) 2026-03-19
EP3976179A1 (en) 2022-04-06
AU2020285336B2 (en) 2026-03-19
IL288405A (en) 2022-01-01
WO2020239952A1 (en) 2020-12-03
JP2025098014A (ja) 2025-07-01
WO2020239951A1 (en) 2020-12-03
MA56022A (fr) 2022-04-06
BR112021022099A2 (pt) 2021-12-28
CO2021017031A2 (es) 2022-01-17
ZA202108273B (en) 2023-07-26
AU2020281923A1 (en) 2022-01-06
PH12021552881A1 (en) 2022-07-25
CA3139019A1 (en) 2020-12-03
KR102921974B1 (ko) 2026-02-05
CN114269432B (zh) 2024-05-07
GEAP202515818A (en) 2025-07-10
SA521430920B1 (ar) 2025-05-21
KR20220016499A (ko) 2022-02-09
JP2022534303A (ja) 2022-07-28
MX2021014113A (es) 2021-12-10
KR102921972B1 (ko) 2026-02-05
US20220227749A1 (en) 2022-07-21
MX2021014115A (es) 2021-12-10
US20230092892A1 (en) 2023-03-23
GEP20257823B (en) 2025-11-10
EP3976180A1 (en) 2022-04-06
BR112021021738A2 (pt) 2021-12-28
JP7644029B2 (ja) 2025-03-11
AU2020285336A1 (en) 2022-01-06
SG11202112187YA (en) 2021-12-30
KR20220016498A (ko) 2022-02-09
CN118239931A (zh) 2024-06-25
JP2022534751A (ja) 2022-08-03
NZ782235A (en) 2025-03-28
US12466820B2 (en) 2025-11-11
CN114269432A (zh) 2022-04-01
CA3139018A1 (en) 2020-12-03
PE20220934A1 (es) 2022-05-31
JP7641917B2 (ja) 2025-03-07
CN113891745B (zh) 2024-05-07
CN113891745A (zh) 2022-01-04

Similar Documents

Publication Publication Date Title
MA56021A (fr) Dérivés d&#39;amino quinazoline servant d&#39;inhibiteurs de p2x3
EP3976624A4 (en) Dna-dependent protein kinase inhibitor
MA51616A (fr) Inhibiteurs d&#39;adn-pk
MA51619A (fr) Inhibiteurs de la protéine kinase dépendante de l&#39;adn
ME03404B (me) Derivati policikličnih amida kao cdk9 inhibitori
EP3906029A4 (en) INHIBITORS OF MENIN-MLL INTERACTION
EP3999517A4 (en) CD73 INHIBITORS
MA52004A (fr) Inhibiteurs d&#39;o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3919491A4 (en) ACT INHIBITOR
MA54521A (fr) Dérivés d&#39;oxopyridine substitués
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu&#39;inhibiteurs de ccr6
EP3820980A4 (en) ESTERQUAT COMPOSITIONS
EP4069688C0 (en) Fused bicyclic heteroaromatic amino compounds with pesticidal action
EP4043450A4 (en) 2h-benzopyran derivatives as crac inhibitors
EP3774739A4 (en) CONDENSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONISTS
EP3992176A4 (en) EP2 ANTAGONIST
MA53648A (fr) Inhibiteurs d&#39;o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP3917926C0 (en) IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITION, THEIR USES
EP3844166A4 (en) SUBSTITUTED MACROCYCLES SUITABLE AS KINASE INHIBITORS
EP3939588A4 (en) USE OF PHOSPHODIESTERAES INHIBITORS
MA53164A (fr) Dérivés de tyrosine amide utilisés en tant qu&#39;inhibiteurs de la rho-kinase
MA51283A (fr) Dérivés de tyrosine en tant qu&#39;inhibiteurs de kinase rho
EP3913022A4 (en) ANCHOR COATING AGENT
EP3855516A4 (en) Composition for sealing
MA51284A (fr) Dérivés d&#39;oxadiazole en tant qu&#39;inhibiteurs de kinase rho